US-based medical data storage platform developer DNAnexus closed a $68m funding round yesterday featuring GV, a corporate venturing subsidiary of technology conglomerate Alphabet, and genomic information supplier WuXi NextCode.
Foresite Capital, TPG Biotech and Claremont Creek Ventures and Innovatus Capital Partners also participated in the round, which included an undisclosed amount of debt financing from Innovatus.
Founded in 2009, DNAnexus has created a cloud-based DNA sequence data analytics and management platform that allows researchers to analyse vast amounts of data securely, integrate it in a compliant environment and collaborate with others.
The system is being used for large-scale projects such as the US National Institutes of Health’s All of Us initiative, which aims to collect and analyse the healthcare data of more than a million people.
The funding will go towards the deployment of DNAnexus Apollo, a more advanced offering that helps biopharmaceutical companies move from the initial stages of identifying a target through the clinical development process.
DNAnexus has raised approximately $173m to date. Wuxi NextCode and GV had both contributed to a $58m round in January 2018 that was led by Foresite Capital and backed by software provider Microsoft, TPG Biotech, Claremont Creek Ventures and MidCap Financial.
Wuxi NextCode provided $15m of funding for the company in 2015, after GV had taken part in a $15m round alongside TPG Biotech, Claremont Creek and First Round the previous year. GV, TPG Biotech, First Round, Felicis Ventures, K9 Ventures and SoftTech VC had already injected $15m in 2011.
